Journal:

Article Title: Influence of Glycosylation on the Efficacy of an Env-Based Vaccine against Simian Immunodeficiency Virus SIVmac239 in a Macaque AIDS Model

doi: 10.1128/JVI.79.16.10386-10396.2005

Figure Lengend Snippet: Env-specific CD4+ T-cell and CD8+ T-cell responses in 12 macaques. A: Env-specific CD8+ T cells in PBMCs were measured by ELISPOT assay for IFN-γ in three groups. B: Env-specific CD4+ T cells in PBMCs were measured by ELISPOT assay for IFN-γ in three groups. ELISPOT results are colored as follows: Δ5G SU-specific T cells (red), wt-SU-specific T cells (green), and TM-specific T cells (yellow). Arrows with a dotted line, arrows with broken line, and arrows with a solid line indicate the time of the third DNA vaccination at 8 weeks p.p., the time of the vaccine boost at 21 weeks p.p., and the time of SIVmac239 challenge at 28 weeks p.p., respectively. C: Comparison of SU-specific CD8+ T cells and CD4+ T cells in PBMCs among the wt-Env vaccine group, the Δ5G Env vaccine group, and the vector control group at 26 weeks p.p. and 4, 7, and 12 days p.i. The numbers of SFC responding to SIVmac239 SU were used to compare the effects of the two vaccines. w, weeks; d, days.

Article Snippet: PBMCs were subjected to the depletion of CD4 + cells with magnet beads coated with anti-human CD4 Ab (Dynal ASA, Oslo, Norway) or subjected to the depletion of CD8 + cells with magnet beads coated with anti-human CD8 Ab (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Enzyme-linked Immunospot, Comparison, Plasmid Preparation, Vaccines

Journal:

Article Title: Influence of Glycosylation on the Efficacy of an Env-Based Vaccine against Simian Immunodeficiency Virus SIVmac239 in a Macaque AIDS Model

doi: 10.1128/JVI.79.16.10386-10396.2005

Figure Lengend Snippet: SIV-specific CD8+ T-cell and CD4+ T-cell responses in 12 animals. A: SIV viral-protein-specific CD8+ T cells in PBMCs were measured by ELISPOT assay for IFN-γ in three groups: vector controls, wt-Env vaccine group, and Δ5G Env vaccines. B: SIV viral-protein-specific CD4+ T cells in PBMCs were measured by ELISPOT assay for IFN-γ in three groups. ELISPOT results of individual SIV proteins are colored as follows: Gag (red), Nef (green), Tat/Rev (blue), Vif/Vpr/Vpx (yellow), and Pol (pink). C: Comparison of cumulated CD8+ T cells or CD4+ T cells specific to the viral proteins Gag, Pol, Nef, Tat/Rev, and Vif/Vpr/VpX between SIV infection-controlled and uncontrolled animals. w, weeks; d, days.

Article Snippet: PBMCs were subjected to the depletion of CD4 + cells with magnet beads coated with anti-human CD4 Ab (Dynal ASA, Oslo, Norway) or subjected to the depletion of CD8 + cells with magnet beads coated with anti-human CD8 Ab (Miltenyi Biotec, Bergisch Gladbach, Germany).

Techniques: Enzyme-linked Immunospot, Plasmid Preparation, Vaccines, Comparison, Infection

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: Graphical illustration of the immunization strategy of GBE@LP for liver cancer treatment. GBE@LP has prolonged circulation in the bloodstream due to surface PEG and selectively accumulates in liver cancer tissues through EPR effect. Meanwhile, DOPE and TGMS give it the property to be released in response to low pH and MMP-9 overexpression in liver cancer microenvironment. GBE@LP delivers drugs into liver cancer, converting uninfiltrated "cold" tumors into highly infiltrated "hot" tumors, while reversing CD8 + T-cell depletion and enhancing cytotoxicity. These effects ultimately enhance immunotherapy for liver cancer.

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Over Expression

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: Liver cancer is a "cold" tumor with high Gal-3 expression. (A) Immunofluorescence images of CD8 + T cells (red) and DAPI (blue) in liver cancer tissues of tumor-bearing mice. (B) Immunohistochemical images of cd8 + T cells in patients with hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and lung cancer (LC) from the HPA database. (C) Expression of Gal-3 in different human cancers was analyzed by HPA database. (D) The expression of Gal-3 in mouse liver cancer tissues and paracancerous tissues was detected by western blotting. (E) The expression of CD8 in the control group and GB1107 treatment group was detected by western blotting. (F) Immunofluorescence images of CD8 + T cells (green), PD-1 (red), and DAPI (blue) in liver cancer tissues and paracancerous tissues of tumor-bearing mice. (G) Immunofluorescence images of CD8 + T cells (green), AR (red), and DAPI (blue) in liver cancer tissues and paracancerous tissues of tumor-bearing mice.

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Expressing, Immunofluorescence, Immunohistochemical staining, Western Blot, Control

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: GBE@LP remodeling the immunosuppressive microenvironment of liver cancer. (A) Flow cytometry scatter graph and (C) Flow cytometry statistical plot of CD8 + T cells infiltration in the tumors of different treatment groups. (B) Flow cytometry histogram and (D) Flow cytometry statistical plot of CD3 + T cells infiltration in the spleen of different treatment groups. (n = 3, p ∗ < 0.05, p ∗∗ < 0.01, p ∗∗∗ < 0.001, p ∗∗∗∗ < 0.0001).

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Flow Cytometry

Journal: Materials Today Bio

Article Title: A pH/MMP-9 smart dual-responsive liposome GBE@LP co-delivers and controls the release of GB1107/BMS1166/Enzalutamide for liver cancer immunotherapy

doi: 10.1016/j.mtbio.2025.101801

Figure Lengend Snippet: (A) Immunofluorescence images of CD8 + T cells (green) and DAPI (blue) in different treatment groups. Scale bars, 1000 μm (top), 50 μm (bottom).

Article Snippet: After deparaffinization and rehydration, the sections were microwaved in 0.01M sodium citrate (pH 6) for 8 min, followed by blocking with 5 % bovine serum albumin (BSA) for 1 h. The sections were then incubated with anti-mouse CD8, anti-mouse PD-1, and anti-mouse AR antibodies (all from Proteintech) at 4 °C for 12 h. After washing, the sections were incubated with Dylight 649 (Goat Anti-Mouse IgG) and Dylight 488 (Goat Anti-Rabbit IgG) antibodies (all from Abbkine) for 1 h, stained with DAPI for 5 min, and then mounted.

Techniques: Immunofluorescence

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors

doi: 10.1016/j.ajps.2022.07.002

Figure Lengend Snippet: In vivo immune responses assessment. (A) Flow cytometry assay of CD80 + or CD86 + gated on CD11c + in the TDLNs of mice. (B) Flow cytometry assay illustrated the percent of CD8a + T cells and CD4 + T cells gated on CD3 + T cells in splenocytes of mice. (C-D) Quantitative percentages of CD80 + or CD86 + expressions gated on CD11c + according to (A). (E) Quantitative percentages of CD8a + T cells and CD4 + T cells in splenocytes according to (B). (F-H) Quantitative analysis of the immune-associated cytokines in serum, as determined by ELISA (IL-2, TNF-α and IFN-γ). ( n = 3, mean ± SD, * P < 0.05, ** P < 0.01 and ## P < 0.0001).

Article Snippet: Fluorochrome-labeled anti-mouse monoclonal antibodies (CD11c-allophycocyanin (APC), CD80-fluorescein isothiocyanate (FITC), CD86-phycoerythrin (PE), CD3-FITC, CD8a-PE, and CD4-APC) were bought from Proteintech.

Techniques: In Vivo, Flow Cytometry, Enzyme-linked Immunosorbent Assay

Journal: Parasite

Article Title: Expression of TIGIT in splenic and circulatory T cells from mice acutely infected with Toxoplasma gondii

doi: 10.1051/parasite/2021010

Figure Lengend Snippet: Changes in TIGIT expression on T cells in different tissues after T. gondii infection. (A) Proportions of TIGIT + cells among CD4 + and CD8 + T cells in T. gondii- infected (RH) and normal mice (Nc) at 7 days after infection. (B) Results of statistical analysis of the percentage of TIGIT + cells among CD4 + T and CD8 + T cells in RH and Nc mice at 7 days after infection. (C) Dynamic changes in the percentages of TIGIT + in T cells at different time points. The results are representative of three independent experiments with five mice in each group per experiment, with data denoting means ± SDs.

Article Snippet: The antibodies used were as follows: anti-mouse Abs against CD3ε-APC-Vio770, mouse (Miltenyi Biotec, 130-117-676), CD8a-PE-Vio770, mouse (Miltenyi Biotec, 130-102-358), PE/DazzleTM 594 anti-mouse CD4 Antibody (BioLegend, 100456), Brilliant Violet 421TM anti-mouse TIGIT (Vstm3) Antibody (BioLegend, 142111), Brilliant Violet 421TM Mouse IgG1, κ Isotype Ctrl Antibody (BioLegend, 400157), FITC anti-mouse CD226 (DNAM-1) (BioLegend, 128803), FITC Rat IgG2b, κ Isotype Ctrl Antibody (BioLegend, 400634), PE anti-mouse/human CD44 (BioLegend, 103007), and Alexa Fluor ® 488 anti-mouse CD62L Antibody (BioLegend, 104420).

Techniques: Expressing, Infection

Journal: Parasite

Article Title: Expression of TIGIT in splenic and circulatory T cells from mice acutely infected with Toxoplasma gondii

doi: 10.1051/parasite/2021010

Figure Lengend Snippet: Changes in CD226 expression on T cells in different tissues after T. gondii infection. (A) Proportions of CD226 + cells among CD4 + T and CD8 + T cells in T. gondii- infected (RH) and normal mice (Nc) at 7 days after infection. (B) Results of statistical analysis of the percentage of CD226 + cells among CD4 + T and CD8 + T in RH and Nc mice at 7 days after infection. (C) Dynamic changes in the percentages of CD226 + T cells at different time points. The results are representative of three independent experiments with five mice in each group per experiment, with data denoting means ± SDs.

Article Snippet: The antibodies used were as follows: anti-mouse Abs against CD3ε-APC-Vio770, mouse (Miltenyi Biotec, 130-117-676), CD8a-PE-Vio770, mouse (Miltenyi Biotec, 130-102-358), PE/DazzleTM 594 anti-mouse CD4 Antibody (BioLegend, 100456), Brilliant Violet 421TM anti-mouse TIGIT (Vstm3) Antibody (BioLegend, 142111), Brilliant Violet 421TM Mouse IgG1, κ Isotype Ctrl Antibody (BioLegend, 400157), FITC anti-mouse CD226 (DNAM-1) (BioLegend, 128803), FITC Rat IgG2b, κ Isotype Ctrl Antibody (BioLegend, 400634), PE anti-mouse/human CD44 (BioLegend, 103007), and Alexa Fluor ® 488 anti-mouse CD62L Antibody (BioLegend, 104420).

Techniques: Expressing, Infection